Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...
Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...
Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...
2d
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...
(RTTNews) - The Phase III WAYPOINT trial results revealed that AstraZeneca (AZN.L, AZN) and Amgen's (AMGN) TEZSPIRE (tezepelumab-ekko) significantly decreased nasal polyp severity, reduced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback